OXFORD, Miss., Oct. 26, 2018 /PRNewswire-PRWeb/ -- Oxford Urology Associates today announced that Dr. Brent
"The UroLift System has fundamentally changed how I treat men in my practice who have symptoms associated with BPH," said Dr. Hardin. "Patients are experiencing rapid symptom relief and are often able to discontinue the use of ongoing BPH medications. It won't be long before the UroLift System becomes the standard of care for treating BPH patients."
Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.
About the UroLift System NeoTract's FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.
About Oxford Urology Associates
At OUA, we strive to provide you with the complete urologic care you deserve. We have built a team of physicians with decades of experience excited to bring you the latest medical innovations. We specialize in Robotic Prostatectomy and Partial Nephrectomy as well as minimally invasive surgeries for BPH (UroLift®), Incontinence (Intersim®) and Pelvic Organ Prolapse (Robotic Sacral Colpopexy). We treat all cancers and benign conditions of the urinary tract. With same day treatment of kidney stones, we are available to serve you when you need us the most. To serve you where you live, we have providers in Oxford, Grenada, Batesville and New Albany. At OUA, we are here for you and we would love to see you today.
Subscribe to our Free Newsletters!